search
Back to results

PET Fibrin Imaging of DVT and PE

Primary Purpose

Pulmonary Embolism, Deep Vein Thrombosis, Venous Thromboembolism

Status
Recruiting
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
64Cu-FBP8
PET-CT imaging
Sponsored by
Peter David Caravan
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Pulmonary Embolism

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • 18 years of age or older with a clinically significant pulmonary embolus (PE) confirmed by a filling defect in CT angiography (CTA), and
  • Subjects must receive the radiotracer injection within 72 hours of their diagnosis.

Exclusion Criteria:

  • Subjects < 18 years of age
  • Time of expected radiotracer injection > 72 hours from the time of a positive venous duplex ultrasound or CT- angiogram
  • Women subjects of childbearing potential who are pregnant, seeking to become pregnant, or have a positive serum pregnancy (beta-HCG) test
  • Unable to lie flat for 45 minutes as assessed by physical examination and medical history (e.g. back pain, arthritis, dyspnea),
  • Weight that exceeds the PET camera table limit (300 kg)
  • The subject will not be enrolled in the study if the radiation exposure for research studies during the prior 12 months, combined with the exposure from this study would exceed 50 mSv (millisievert).
  • Due to the radiation exposure from imaging studies, all women of childbearing potential will be required to have a negative serum pregnancy test performed prior to any imaging procedures on the same day (if not already done that day). Patients with a positive serum pregnancy test will be excluded. Breast feeding women will also be excluded.
  • A pre-existing condition or use of a medication including vasopressors and tPA (tissue Plasminogen Activator) that in the opinion of the investigator may place the subject at a substantially increased risk
  • Hemodynamic instability, including requiring escalating doses of vasopressor medication.
  • No groups designated as "special vulnerable populations" will be studied.
  • No exclusions will be made based on race, sex, or ethnic origin.
  • 64Cu-FBP8 (Copper-64 labeled fibrin binding probe 8) is cleared by the kidneys, patients with eGFR (estimated Glomerular Filtration Rate ) < 30 will be excluded.

Sites / Locations

  • Massachusetts General HospitalRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Acute pulmonary embolism

Arm Description

Subjects will receive 64Cu-FBP8 and undergo PET-CT imaging.

Outcomes

Primary Outcome Measures

Location of the thrombus within the lungs
To determine the location of the thrombus regions of interest (ROIs) within the lungs using PET-CT imaging in comparison to the ROI of filling defects on CT-angiogram.
Location of clot burden measurements within the thigh
To determine the location of the thrombus ROI within the thigh using PET-CT imaging in comparison to the clot on venous duplex ultrasound.
Assessment of 64Cu-FBP8 fibrin activity in the pelvic and upper extremity
The prevalence of high 64Cu-FBP8 fibrin activity in the pelvic ROI and upper extremity ROI's will be reported.

Secondary Outcome Measures

Correlation between normalized 64Cu-FBP8 fibrin activity and plasma D-dimer
Correlation of the total fibrin activity in the imaged fields, excluding the liver, gallbladder, kidneys and urinary bladder normalized by injected dose with the plasma D-dimer.
Overall clot burden within the lungs
Overall clot burden calculated as sum of 64Cu-FBP8 activity within a thrombus ROI(s) within the lungs.
Overall clot burden within the thigh
Overall clot burden calculated as sum of 64Cu-FBP8 activity within a thrombus ROI(s) within the thigh.

Full Information

First Posted
July 10, 2019
Last Updated
July 15, 2019
Sponsor
Peter David Caravan
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
search

1. Study Identification

Unique Protocol Identification Number
NCT04022915
Brief Title
PET Fibrin Imaging of DVT and PE
Official Title
PET Fibrin Imaging of DVT and PE
Study Type
Interventional

2. Study Status

Record Verification Date
July 2019
Overall Recruitment Status
Recruiting
Study Start Date
May 13, 2019 (Actual)
Primary Completion Date
May 13, 2023 (Anticipated)
Study Completion Date
May 31, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Peter David Caravan
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study aims to investigate a novel positron emission tomography(PET)-probe for imaging of fresh intravascular blood clots in pulmonary embolism (PE) and deep venous thrombosis (DVT).
Detailed Description
Venous thromboembolism (VTE) is one of the most common causes of death in the United States, resulting in more than 100,000 deaths annually. Current diagnostic techniques rely on indirect measures of clot for diagnosis and therefore suffer from the problems of both under and overdiagnosis and cannot always be performed on patients with renal failure and lung disease. In this study, we will use the novel fibrin-specific probe 64CU-FBP8 (Copper-64 labeled fibrin binding probe 8) for PET imaging of fresh blood clots in PE and DVT. Our long-term goal is to establish a novel thrombus body scan (TBS) using 64CU-FBP8 for PET imaging to overcome the limitations of indirect venous thromboembolism diagnosis, and, with one single test, provide a total-body assessment of fresh intravascular clot.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pulmonary Embolism, Deep Vein Thrombosis, Venous Thromboembolism

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Model Description
Subjects with acute pulmonary embolism meeting the inclusion criteria will be enrolled.
Masking
None (Open Label)
Allocation
N/A
Enrollment
80 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Acute pulmonary embolism
Arm Type
Experimental
Arm Description
Subjects will receive 64Cu-FBP8 and undergo PET-CT imaging.
Intervention Type
Drug
Intervention Name(s)
64Cu-FBP8
Intervention Description
Up to 10 mCi (millicurie) 64Cu-FBP8 will be administered to each subject.
Intervention Type
Diagnostic Test
Intervention Name(s)
PET-CT imaging
Intervention Description
All subjects will undergo PET-CT imaging after administration of 64Cu-FBP8.
Primary Outcome Measure Information:
Title
Location of the thrombus within the lungs
Description
To determine the location of the thrombus regions of interest (ROIs) within the lungs using PET-CT imaging in comparison to the ROI of filling defects on CT-angiogram.
Time Frame
4 hours
Title
Location of clot burden measurements within the thigh
Description
To determine the location of the thrombus ROI within the thigh using PET-CT imaging in comparison to the clot on venous duplex ultrasound.
Time Frame
4 hours
Title
Assessment of 64Cu-FBP8 fibrin activity in the pelvic and upper extremity
Description
The prevalence of high 64Cu-FBP8 fibrin activity in the pelvic ROI and upper extremity ROI's will be reported.
Time Frame
4 hours
Secondary Outcome Measure Information:
Title
Correlation between normalized 64Cu-FBP8 fibrin activity and plasma D-dimer
Description
Correlation of the total fibrin activity in the imaged fields, excluding the liver, gallbladder, kidneys and urinary bladder normalized by injected dose with the plasma D-dimer.
Time Frame
4 hours
Title
Overall clot burden within the lungs
Description
Overall clot burden calculated as sum of 64Cu-FBP8 activity within a thrombus ROI(s) within the lungs.
Time Frame
4 hours
Title
Overall clot burden within the thigh
Description
Overall clot burden calculated as sum of 64Cu-FBP8 activity within a thrombus ROI(s) within the thigh.
Time Frame
4 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 18 years of age or older with a clinically significant pulmonary embolus (PE) confirmed by a filling defect in CT angiography (CTA), and Subjects must receive the radiotracer injection within 72 hours of their diagnosis. Exclusion Criteria: Subjects < 18 years of age Time of expected radiotracer injection > 72 hours from the time of a positive venous duplex ultrasound or CT- angiogram Women subjects of childbearing potential who are pregnant, seeking to become pregnant, or have a positive serum pregnancy (beta-HCG) test Unable to lie flat for 45 minutes as assessed by physical examination and medical history (e.g. back pain, arthritis, dyspnea), Weight that exceeds the PET camera table limit (300 kg) The subject will not be enrolled in the study if the radiation exposure for research studies during the prior 12 months, combined with the exposure from this study would exceed 50 mSv (millisievert). Due to the radiation exposure from imaging studies, all women of childbearing potential will be required to have a negative serum pregnancy test performed prior to any imaging procedures on the same day (if not already done that day). Patients with a positive serum pregnancy test will be excluded. Breast feeding women will also be excluded. A pre-existing condition or use of a medication including vasopressors and tPA (tissue Plasminogen Activator) that in the opinion of the investigator may place the subject at a substantially increased risk Hemodynamic instability, including requiring escalating doses of vasopressor medication. No groups designated as "special vulnerable populations" will be studied. No exclusions will be made based on race, sex, or ethnic origin. 64Cu-FBP8 (Copper-64 labeled fibrin binding probe 8) is cleared by the kidneys, patients with eGFR (estimated Glomerular Filtration Rate ) < 30 will be excluded.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Tilo Winkler, PhD
Phone
617-724-4083
Email
twinkler@mgh.harvard.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Mamary T Kone, MD, MPH
Phone
617-726-1082
Email
mkone@mgh.harvard.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Tilo Winkler, PhD
Organizational Affiliation
Massachusetts General Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Massachusetts General Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tilo Winkler, PhD
Phone
617-724-4083
Email
twinkler@mgh.harvard.edu

12. IPD Sharing Statement

Learn more about this trial

PET Fibrin Imaging of DVT and PE

We'll reach out to this number within 24 hrs